GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remed Co Ltd (XKRX:302550) » Definitions » Net Income

Remed Co (XKRX:302550) Net Income : ₩797 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Remed Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Remed Co's Net Income for the three months ended in Dec. 2023 was ₩232 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was ₩797 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Remed Co's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was ₩7.55.


Remed Co Net Income Historical Data

The historical data trend for Remed Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remed Co Net Income Chart

Remed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial 4,363.10 -1,833.71 752.33 4,000.13 797.17

Remed Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,167.38 273.53 -846.43 1,138.13 231.94

Remed Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Remed Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=979.659+-660.414+0+477.924
=797

Remed Co's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=330.484+-228.351+0+129.807
=232

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩797 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remed Co  (XKRX:302550) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Remed Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Remed Co Net Income Related Terms

Thank you for viewing the detailed overview of Remed Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Remed Co (XKRX:302550) Business Description

Traded in Other Exchanges
N/A
Address
187 Techno 2-ro, No 301-303, Gwanpyeong-dong, Yuseong-gu, Daejeon, KOR, 34025
Remed Co Ltd is a Korean medical equipment manufacturing company. The company is engaged in researching and developing products to treat brain disorders such as depression, anxiety, stroke and Parkin's. It has developed TMS device and is manufacturing pain therapy devices using advanced electromagnetic stimulation, shockwave (RSWT) and laser technologies. Its products offerings include Transcranial Magnetic simulator for brain, Electromagnetic simulators including Salus Talent, Salus Talent A, Salus Talent Pro, and Optimus Pro for pain therapy; and Rosetta, Salus RSWT and Optimus Pro as a part of Extracorporeal Shockwave Therapy. It also offers Electrosurgical units from REMED including ELPIS 4L, ELPIS 4, ELPIS 3, and ELPIS2.

Remed Co (XKRX:302550) Headlines

No Headlines